Streetbeat News

Stock Prices

APLS

CAVA

CRWD

FDX

JAKK

PYPL

SBGI

WIX

Top Wall Street analysts have updated their price targets and ratings for several companies, including CrowdStrike, JAKKS Pacific, CAVA Group, and others. Notably, CrowdStrike's price target was raised by Keybanc, leading to an 8.1% increase in its stock price.

Portfolio Pulse from Avi Kapoor

September 23, 2024 | 12:12 pm

BDTX

BHVN

VTYX

Black Diamond Therapeutics, Ventyx Biosciences, and Biohaven saw significant stock movements. Black Diamond's shares rose 54% due to positive Phase 2 data for BDTX-1535. Ventyx Biosciences announced a $27M investment from Sanofi, boosting shares by 42%. Biohaven's shares increased 26% after successful study results for Troriluzole.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:10 pm

ACTU

Actuate Therapeutics, Inc. has published new research on elraglusib, a GSK-3β inhibitor, highlighting its potential as an immune modulator in treating neuroblastoma. The study suggests elraglusib could activate the immune system in cancers unresponsive to checkpoint inhibitors.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:08 pm

AVIV

BNPQY

DFIV

HSBC

HSBC has agreed to sell its German private banking business to BNP Paribas, aiming to enhance BNP's wealth management presence in Germany. The deal is expected to close in the second half of 2025, pending regulatory approvals. HSBC shares rose following the announcement.

Portfolio Pulse from Lekha Gupta

September 23, 2024 | 12:05 pm

CDTX

Cidara Therapeutics has initiated dosing in the Phase 2b NAVIGATE trial for CD388, a drug aimed at preventing seasonal influenza. This marks a significant step in the development of CD388, potentially impacting Cidara's future prospects.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:04 pm

VTYX

Ventyx Biosciences shares rose following a $27 million investment from Sanofi, indicating positive market sentiment and potential growth opportunities for the company.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:02 pm

CRWD

Over the past three months, 48 analysts have shared insights on CrowdStrike Holdings (NASDAQ:CRWD), with a mix of bullish and bearish opinions. The average 12-month price target has decreased by 8.25% to $321.38. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. CrowdStrike, a cloud-based cybersecurity company, has shown strong revenue growth and profitability but faces challenges in return on equity and asset utilization.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 12:01 pm

GDDY

The article discusses recent analyst ratings for GoDaddy (NYSE:GDDY), highlighting a range of perspectives from bullish to indifferent. Analysts have set a 12-month average price target of $171.91, reflecting a 10.62% increase from the previous target. GoDaddy's financial performance is analyzed, showing strong profitability and effective asset utilization, but challenges in debt management.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 12:00 pm

CAVA

Analysts have mixed ratings for Cava Group (NYSE:CAVA), with a recent trend towards more bullish sentiments. The average 12-month price target has increased by 17.64% to $111.76. Cava Group shows strong revenue growth and profitability, but faces challenges with return on equity.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 12:00 pm

Analysts have varied opinions on Fiserv (NYSE:FI), with recent ratings showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $185.75, indicating positive expectations. Fiserv's financial performance shows strong net margins but challenges in ROE and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 12:00 pm